Treatment of T-Cell Lymphoma using 10-propargyl-10-deazaaminopterin
T cell lymphoma is treated by administering to a patient suffering from T cell lymphoma a therapeutically effective amount of 10-propargyl-10-deazaaminopterin. Remission is observed in human patients, even with drug resistant T cell lymphoma at weekly dosages levels as low as 30 mg/m 2 . In general, the 10-propargyl-10-deazaaminopterin is administered in an amount of from 30 to 275 mg/m 2 per dose.
1 . A method for treatment of T cell lymphoma comprising administering to a human patient diagnosed as having a T cell lymphoma a composition comprising a therapeutically effective amount of 10-propargyl-10-deazaaminopterin.
2 . The method of claim 1 , wherein the 10-propargyl-10-deazaaminopterin is substantially free of 10-deazaaminopterin.
3 . The method of claim 1 , wherein the 10-propargyl-10-deazaaminopterin is administered in an amount of from 30 to 275 mg/m 2 per dose.
4 . The method of claim 3 , wherein the 10-propargyl-10-deazaaminopterin is administered weekly.
5 . The method of claim 4 , wherein the 10-propargyl-10-deazaaminopterin is administered in a dose of 30 mg/m 2 .
6 . The method of claim 4 , wherein the 10-propargyl-10-deazaaminopterin is administered in an amount of from 30 to 150 mg,/m 2 per dose.
7 . The method of claim 1 , wherein the 10-propargyl-10-deazaaminopterin is administered biweekly.
8 . The method of claim 7 , wherein the 10-propargyl-10-deazaaminopterin is administered in a dosage amount of 135 to 275 mg/m 2 .